Glooko Announces New ‘Glooko Advise’ Decision Support Product Line at the 2016 American Diabetes Association Conference
Mountain View, California (PRWEB) June 10, 2016 -- Glooko Inc., the leading unified platform for diabetes management, today announced its new ‘Glooko Advise’ product line, including ‘Glooko Personal Advisor’ and ‘Glooko Clinical Advisor’, which enables both people with diabetes (PWD) and clinicians with practical diabetes decision support. Glooko will demonstrate the new product functionalities at the 76th Annual Scientific Sessions of the American Diabetes Association from June 10 - 13, 2016, in New Orleans.
Glooko Personal Advisor aims to help PWDs better understand their retrospective diabetes data and improve daily decisions by using proprietary pattern recognition algorithms to recognize trends and deliver targeted educational content based on those trends. Personal Advisor will identify numerous trends including PWD’s ‘Best Day’, the ‘Time of Day’ when glucose runs high or low, and ‘Summary Statistics’ that recognizes improvements or regressions in the Average BG and frequency of highs, lows, and in range readings.
“Providing this immediately understandable and novel approach for describing and interacting with diabetes data can truly illuminate learnings for people with diabetes to help them achieve their personal goals,” said Dr. David Kerr, Director of Research and Innovation at the William Sansum Diabetes Center in Santa Barbara. He continued, “Without doubt the new Glooko Advise product line provides valuable and relevant tools for people with diabetes and their clinicians that will enable the achievement of the desired outcomes in diabetes care.”
Glooko Clinical Advisor will include both AACE guidelines and clinical algorithms that, once initialized and approved by a clinician, can aid the clinician to more effectively optimize diabetes therapy in the weeks or months between in-clinic appointments. Glooko will demonstrate products within Clinical Advisor that enable:
1. Mobile Insulin Dosing - Using Glooko’s Mobile Insulin Dosing system (MIDS), clinicians can configure an insulin prescription for PWDs starting on long-acting insulin using a standard or custom insulin titration method based on the AACE guidelines. After the configuration, Glooko’s Mobile App will automatically prompt, recommend and remind PWDs of insulin adjustments based on glucose readings and the insulin titration configuration defined by their clinician.
2. Insulin Pump Settings Adjustments - Glooko’s first built-in 3rd party algorithm developed by DreaMed Diabetes recommends adjustments to critical insulin-pump settings, including basal rates and insulin-to-carb ratios. Through the Glooko interface and leveraging Glooko’s easy data syncing and management platform, clinicians can review DreaMed algorithm recommendations and make therapeutic regimen decisions. Within a patient record in the Glooko Population Tracker, the clinician can approve, adjust, or prevent the recommendations from being delivered to the patient.
“With the Glooko Advise product line we are executing our vision around personalized medicine where we aim to deliver improved daily decision support for people with diabetes and the teams who care for them. Clinicians clearly need additional tools to allow them to deliver more efficient care in order to handle the increasing number of PWD’s on long acting insulin - Glooko’s Mobile Insulin Dosing System will meet this need” said Rick Altinger, CEO of Glooko.
DreaMed will deliver algorithms for Pump Settings adjustments by building on Glooko’s Application Programming Interfaces (APIs), which partner companies can leverage for offering FDA-regulated algorithms within Glooko Clinical Advisor. Funding for the development of this first integrated algorithm comes from a grant from the Helmsley Charitable Trust, announced earlier this year. The grant aims to facilitate and optimize insulin pump care for people with Type 1 diabetes.
Glooko Personal Advisor will be available in July 2016. The components of Glooko Clinical Advisor will be deployed for clinical studies in the second half of 2016. For more information, contact Glooko.
ABOUT GLOOKO
Glooko is the world’s leading Unified Platform for Diabetes Management and is trusted by the world’s leaders in diabetes care. Glooko provides an FDA-cleared, HIPAA-compliant web and mobile application, which aims to improve health outcomes for people with diabetes, in turn reducing costs for payers and the healthcare system. Glooko seamlessly syncs with over 50 blood glucose meters, pumps, CGMs, fitness and activity trackers, and supplies timely, verified patient data such as blood glucose, carbs, insulin, blood pressure, diet and weight data. Glooko’s mobile app enables patients to easily track and proactively manage all aspects of their diabetes care. Glooko’s Population Management web app and API’s offers diabetes-centric analytics and supply insightful reports, graphs and risk flags to patients, health systems and payers, as well as third party developers. Learn more at http://www.glooko.com, and follow us at Twitter.com/GlookoInc and Facebook.com/Glooko.
Vikram Singh, Glooko, Inc., +1 (925) 487-1461, [email protected]
Share this article